Pay-(FDA)-Per-(Pre)View of DTC Posted: September 1, 2006 Is mandatory review of all DTC ads by FDA in the cards? More precisely, is it on the bargaining table as FDA and the drug industry negotiate User Fee levels for the next five years? What could be some of the concessions demanded by the industry for mandatory review of DTC? For the answers to these questions and more, see today's post to Pharma Marketing Blog. For more posts in related topic areas, see: DTC Advertising FDA PhRMA If you wish to receive notice by email whenever a post is made to Pharma Marketing Blog, please subscribe. Enter your Email Address | Return to Pharma Marketing Blog Topics |

Special Supplement Relationship Marketing Direct, Targeted, Permission-based Marketing Builds Relationships, Increases ROI and Improves Patient Compliance This collection of Pharma Marketing News articles, blog posts, and survey results provides you with an excellent introduction to the many facets and uses of pharmaceutical relationship marketing. TABLE OF CONTENTS Order and pay for this Special Supplement now using your credit card ONLY $29.95 PDF file delivered to you by email (usually within minutes of placing your order): If you wish to be pay by check or credit card off-line, please use: Printable Order Form